

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
04 April 2024 (04.04.2024)



(10) International Publication Number
WO 2024/073635 A3

(51) International Patent Classification:

C12N 15/85 (2006.01) A61K 38/17 (2006.01)
C12N 15/86 (2006.01) A61P 27/16 (2006.01)
C12N 15/87 (2006.01) C12N 15/861 (2006.01)
A61K 48/00 (2006.01) C07K 14/47 (2006.01)

(21) International Application Number:

PCT/US2023/075471

(22) International Filing Date:

29 September 2023 (29.09.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/412,217 30 September 2022 (30.09.2022) US
63/463,630 03 May 2023 (03.05.2023) US

(71) Applicant: **DECIBEL THERAPEUTICS, INC.**
[US/US]; 1325 Boylston Street, Suite 500, Boston, MA
02215 (US).

(72) Inventors: **GIBSON, Tyler**; 1325 Boylston Street, Suite
500, Boston, MA 02215 (US). **KOWALCZYK, Monika**;
1325 Boylston Street, Suite 500, Boston, MA 02215 (US).
LEBO, Kevin; 1325 Boylston Street, Suite 500, Boston,
MA 02215 (US). **MANCHANDA, Aayushi**; 1325 Boyl-
ston Street, Suite 500, Boston, MA 02215 (US). **SELLON,**
Jonathan, B.; 1325 Boylston Street, Suite 500, Boston, MA
02215 (US). **SO, Kathy**; 1325 Boylston Street, Suite 500,
Boston, MA 02215 (US).

(74) Agent: **BELLIVEAU, Michael, J.** et al.; Clark & Elbing
LLP, 101 Federal Street, 15th Floor, Boston, MA 02110
(US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(88) Date of publication of the international search report:

13 June 2024 (13.06.2024)

(54) Title: SLC26A4 REGULATORY ELEMENTS AND USES THEREOF

(57) Abstract: The disclosure provides SLC26A4 promoters and SLC26A4 enhancers, as well as vectors containing the same, that can be used to restrict gene expression to SLC26A4-expressing cells and to increase gene expression in these cells, such as interdental cells, root cells, spiral prominence cells, and vestibular supporting cells. The SLC26A4 enhancers and SLC26A4 promoters described herein may be operably linked to a polynucleotide, such as a transgene, encoding an expression product and used for the treatment of subjects having or at risk of developing hearing loss or vestibular dysfunction.



WO 2024/073635 A3